Skin and skin structure infections: Treatment with newer generation fluoroquinolones

Therapeutics and Clinical Risk Management

Volumn 3, Issue 2, 2007, Pages 309-317

  Giordano, Philip ^a,b   Weber, Kurt ^a   Gesin, Gail ^a   Kubert, Jason ^a  

^a ORLANDO REGIONAL MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

Complicated skin and skin structure infections; Fluoroquinolone; Gatifloxacin; Levofloxacin; Moxifloxacin; Uncomplicated skin and skin structure infections

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTACID AGENT; ANTIBIOTIC AGENT; CEFALEXIN; CEFDINIR; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COTRIMOXAZOLE; CYTOCHROME P450; DICLOXACILLIN; DIDANOSINE; GATIFLOXACIN; IRON; LEVOFLOXACIN; MACROLIDE; MAGNESIUM; METICILLIN; MOXIFLOXACIN; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SUCRALFATE; TIMENTIN; VANCOMYCIN; ZINC;

ANAEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; BACTERIAL INFECTION; CELLULITIS; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CREATININE CLEARANCE; DECUBITUS; DIABETES MELLITUS; DIABETIC FOOT; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FOOD; FOOD AND DRUG ADMINISTRATION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEADACHE; HEALTH CARE UTILIZATION; HEART ARRHYTHMIA; HEMODIALYSIS; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSOMNIA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NAUSEA; PATHOGENESIS; PATIENT CARE; PRESCRIPTION; QT PROLONGATION; REVIEW; SKIN ABSCESS; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PYOGENES; TORSADE DES POINTES; TREATMENT DURATION; TREATMENT OUTCOME; VAGINITIS; WOUND INFECTION;

EID: 34250011998     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: 10.2147/tcrm.2007.3.2.309     Document Type: Review

References (62)

1. Amankwa K, Krishnan SC, Tisdale JE. 2004. Torsades de pointes associated with fluoroquinolones: importance of concomitant risk factors. Clin Pharmacol Ther, 75:242-7.
2. Anzueto A, Niederman MS, Pearle J, et al. 2006. Community acquired pneumonia recovery in the elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Clin Infect Dis, 42:73-81.
3. [AMR] Arlington Medical Resources. 2004. Hospital Antibiotic Market Database
4. [online]. Accessed on 25 July 2006. URL: http://www.amr-data.com/.
5. Ball P, Stahlman R, Kubin R, et al. 2004. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Clin Ther, 26:940-50.
6. Ball P. 2000. Quinolone-induced QT interval prolongation: a not-so-unexpected class effect. J Antimicrob Chemother, 45:557-9.
7. Bayer Pharmaceuticals Co. 2005. Avelox (moxifloxacin) package insert. Westhaven, CT: Bayer Pharmaceuticals.
8. Bignardi GE. 1998. Risk factors for Claustridium difficile infection. J Hosp Infect, 40:1-15.
9. Bertino JS, Owens RC Jr., Carnes TD, et al. 2002. Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors. Clin Infect Dis, 34:861-3.
10. Blondeau JM, Hansen G, Metzler KL, et al. 2003. In vitro susceptibility of 4903 bacterial isolates to gemifloxacin and advanced fluoroquinolones. Int J Antimcrob Agents, 22:147-54.
11. Bristol-Myers Squibb Co. 2006a. Tequin (gatifloxacin) package insert. Princeton, NJ: Bristol-Myers Squibb Co.
12. Bristol-Myers Squibb Co. 2006b. Dear Health Care Provider letter [online]. Accessed 10 April 2006. URL: www.fda.gov/medWatch/safety/2006/ tequin_DHCP.pdf.
13. [CDC] Center for Disease Control. 2001. Incidence of soft tissue infections:
14. San Francisco General Hospital - 1996-2000. MMWR, 50:381-4.
15. [CLSI] Clinical and Laboratory Standards Institute. 2006. Performance standards for antimicrobial susceptibility testing. Sixteenth Informational Supplement. CLSI document M100-S16.
16. Dial S, Alrasadi K, Huang A, et al. 2004. Risk of Clostridium dificile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. Can Med Assoc J, 171:33-8.
17. DiNubile MJ, Lipsky BA. 2004. Complicated Infections of skin and skin structure infections: When infection is more than skin deep. J Antimicrob Chemother, 53:37-50.
18. Edmiston CE, Krepel CJ, Seabrook GR, et al. 2004. In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections. Antimicrob Agents Chemother, 48:1012-16.
19. [EMEA] European Agency for the Evaluation of Medicinal Products; Committee for Proprietary Medicinal Products. 2006. Points to consider: the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products [online]. Accessed 10 April 2006. URL: www.coresearch.biz/regulations/cpmp.pdf.
20. [FDA] Food and Drug Administration. 1998. Guidance for industry: uncomplicated skin and skin structure infections - Developing antimicrobial drugs for therapy [online]. Accessed 10 April 2005. URL: www.fda.gov/cder/guidance/2566dft.pdf.
21. Fiebelkorn KR, Crawford SA, McElmeel ML, et al. 2003. Practical disc diffusion method for detection of inducible clindamycin resistance in Staphylococcus aureus and coagulase-negative staphylococci. J Clin Microbiol, 41:4740-4.
22. File TM Jr. Tan JS. 1995. Treatment of skin and soft-tissue infections. Am J Surgery, 169(5A Suppl):27S-33S.
23. Firsov AA, Lubenko IY, Vostrov SN, et al. 2005. Antistaphylococcal effect related to the area under the curve/MIC ratio in an in vitro dynamic model: predicted breakpoints versus clinically achievable values for seven fluoroquinolones. Antimicrob Agents Chemother, 49:2642-7.
24. Forrest A, Nix DE, Ballow CH, et al. 1993. Pharmocodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother, 37:1073-81.
25. Frazee BW, Lynn J, Charlebois ED, et al. 2005. High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections. Ann Emerg Med, 45:311-20.
26. Furlanut M, Brollo L, Lugatti,E, et al. 2003. Pharmacokinetic aspects of levofloxacin 500 mg once daily during sequential intravenous/oral therapy in patients with lower respiratory tract infections. J Antimicrob Chemother, 51:101-6.
27. Gandhi PJ, Menezes PA, Vu HT, et al. 2003. Fluconazole- and levofloxacin-induced torsades de pointes in an intensive care unit patient. Am J Health-Syst Pharm, 60:2479-83.
28. Gerding DN. 2004. Clindamycin, cephalosporins, fluoroquinolones, and Claustridium difficile-associated: this is an antimicrobial resistance problem. Clin Infect Dis, 38:646-8.
29. Giordano P, Song J, Pertel P, et al. 2005. Sequential intravenous/oral moxifloxacin versus intravenous pipericillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection. Inter J Antimicro Agents, 26:357-65.
30. Graffunder EM, Venezia RA. 2002. Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J Antimicrob Chemother, 49:999-1005.
31. Graham DR, Talan DA, Nichols RL, et al. 2002. Once-daily, high dose levofloxacin versus ticaricillin-clavulanate alone or followed by amoxicillin for complicated skin and skin structure infections: A randomized, open label trial. Clin Inf Dis, 35:381-9.
32. Guay D. 2003. Treatment of bacterial skin and skin structure infections. Expert Opin Pharmacother, 4:1259-75.
33. Hagiwara T, Satoh S, Kasai Y, et al. 2001. A comparative study of the various fluoroquinolone antibacterial agents on the cardiac action potential in guinea pig right ventricular myocardium. Jpn J Pharmacol, 87:231-4.
34. Iannini PB, Circiumaru I. 2001. Gatifloxacin-induced QTc prolongation and ventricular tachycardia. Pharmacotherapy, 21:361.
35. Johnson S, Gerding DN. 1998. Clostridium difficile-associated diarrhea. Clin Infect Dis, 26:1027-34.
36. Lee MC, Rios AM, Aten MF, et al. 2004. Management and outcomes of skin and soft tissue abcesses coused by community acquired methicillin resistant Staphylococcus aureus. Pediatri Infect Dis J, 23:123-7.
37. Loo VG, Poirier L, Miller MA, et al. 2005. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associatecd diarrhea with high morbidity and mortality. N Engl J Med, 353(23):2442-9.
38. Lubasch A, Keller I, Borner K, et al. 2000. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents and Chemother, 44:2600-3.
39. Manhold C, von Rolbieki U, Brase R, et al. 1998. Outbreaks of Staphylococcus aureus infections during treatment of late onset pneumonia with ciprofloxacin in a prospective randomized study. Intensive Care Med, 24:1327-30.
40. Milatovic D, Schmitz F, Brisse S, et al. 2000. In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates. Antimicrob Agents Chemother, 44:1102-7.
41. Mulligan ME, Miller SD, McFarland, et al. 1993. Elevated levels of serum immunoglobulins in asymptomatic carriers of Clostridium difficile. Clin Infect Dis. 16(suppl 4):S239-44.
42. Naimi TS, LeDell KH, Como-Sabetti K, et al. 2003. Comparison of community- and health care-acquired methicillin resistant Staphylococcus aureus infection. JAMA, 290:2976-84.
43. Nichols RL, Smith JW, Gentry LO, et al. 1997. Multi-center, randomized study comparing levofloxacin and ciprofloxacin for uncomplicated skin and skin structure infections. South Med J, 90:1193-200.
44. Nichols RL. 1999. Optimal treatment of complicated skin and skin structure infections. J Antimicrob Chemother, 44:19-23.
45. Noel AR, Bowker KE, Macgowan AP. 2005. Pharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic model. Antimicrob Agents Chemother, 49:4234-9.
46. Ortho-McNeil Pharmaceutical. 2005. Levaquin (levofloxacin) package insert. Raritan, NJ.
47. Owens RC. 2001. Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes. Pharmacotherapy, 21:301-19.
48. Owens RC. 2004. QT prolongation with antimicrobial agents: understanding the significance. Drugs, 64:1091-124.
49. Owens RC. 2006. Claustridium difficile- associated disease: An emerging threat to patient safety. Pharmacotherapy, 26(3): 299-311.
50. Parish LC, Routh HB, Miskin B, et al. 2000. Moxifloxacin versus cephalexin in the treatment of uncomplicated skin infections. Int J Clin Pract, 54:497-503.
51. Raghavan R, Linden PK. 2004. Newer treatment options for skin and soft tissue infections. Drugs, 64:1621-42.
52. Rennie RP, Jones RN, Mutnick AH, et al. 2003. Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the Sentry antimicrobial surveillance program. Diagn Microbio Infect Dis, 45:287-93.
53. Stevens DL, Bisno AL, Chambers HF. 2005. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis, 41:1373-406.
54. Tarshis GA, Miskin BM, Jones TM, et al. 2001. Once-daily oral gatifloxacin versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infections: double-blind, multicenter, randomized study. Antimicrob Agents Chemother, 45:2358-62.
55. Trampuz A, Laifer G. 2002. Pharmacokinetics and pharmacodynamics of gatifloxacin against Streptococcus pneumoniae and Staphylococcus aureus in human skin blister fluid. Antimicrob Agents Chemother, 46:3630-3.
56. Trampuz A, Wenk M, Rajacic Z, et al. 2000. Pharmacokinetics and pharmacodynamics of levofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in human skin blister fluid. Antimicrob Agents Chemother, 44:1352-5.
57. Weber SG, Gold HS, Hooper DC, et al. 2003. Fluoroquinolones and the risk of methicillin resistant Staph aureus in hospitalized patients. Emerg Infect Dis, 9:1415-22.
58. Wickersham RM, Schweain SL (eds). 2005. Drug facts and comparisons. St. Louis: Wolters Kluwer Health, Inc.
59. Wise R, Andrews JM, Marshall G, et al. 1999. Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral and intravenous administration. Antimicrob Agents and Chemother, 43:1508-10.
60. Wright DH, Brown GH, Peterson ML, et al. 2000. Application of fluoroquinolone pharmacodynamics. J Antimocrob Chemother, 46:669-83.
61. Yap YG, Camm AJ. 2003. Drug-induced QT prolongation and torsades de pointes. Heart, 89:1363-72.
62. Yee SY, Kuti JL, Nicolau DP. 2005. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance. Surg Infect, 6:283-95.